← All trials
NCT04445194
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 22, 2020
- Primary completion
- Oct 22, 2020
- Completion date
- Sep 20, 2021
- First posted
- Jun 24, 2020
- Last posted
- Dec 3, 2020
- Enrollment
- 50
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Lead sponsor
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityOverall official - principal investigator
- Capital Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.